

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHSGG&C?

- If a medicine is not routinely available and included in the GGC Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. NHSGG&C and all health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Greater Glasgow and Clyde's decisions on new medicines.

If you need more information on medicines decisions in NHS Greater Glasgow and Clyde, please email ggc.medicines@ggc.scot.nhs.uk

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

5-aminolaevulinic acid (as hydrochloride) gel Ameluz® 1260/17	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.	Routinely available in line with national guidance	26/02/2018
	http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_Resubmission_FINAL_Jan_0218_for_website.pdf		
Adalimumab subcutaneous injection Humira® 1305/18	Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	Not routinely available as not recommended for use in NHSScotland	26/02/2018
	http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Non_Sub_FINAL_Dec_2017_for_website.pdf		
Baricitinib tablets Olumiant® 1265/17	Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.	Routinely available in line with local or regional guidance	26/02/2018
	http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf		
Carbetocin injection Pabal® 309/06	For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia	Not routinely available as not recommended for use in NHSScotland	26/02/2018
	http://www.scottishmedicines.org.uk/files/advice/carbetocin_Pabal_FINAL_Dec_2017_for_website.pdf		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Ceftaroline fosamil infusion Zinforo® 1306/18	treatment of: - complicated skin and soft tissue infections in children from the age of 2 months - community-acquired pneumonia in children from the age of 2 months http://www.scottishmedicines.org.uk/files/advice/ceftaroline_fosamil_Zinforo_Non_Sub_FINAL_Dec_2017_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Ceftazadime with Avibactam Infusion Zavicefta 1307/18	Treatment of the following infections in adults: 1) complicated intra-abdominal Infection (cIAI); 2) complicated urinary tract infection (cUTI), including pyelonephritis; 3) hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); 4) infections due to aerobic Gram-negative organisms in adult patients with limited treatment options http://www.scottishmedicines.org.uk/files/advice/ceftazidime_avibactam_Zavicefta_Non_Sub_FINAL_Dec_2017_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Cladribine tablet Mavenclad® 1300/18	Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. http://www.scottishmedicines.org.uk/files/advice/cladribine_Mavenclad_FINAL_Jan_2018_Amended_07.02.18_for_website.pdf	Routinely available in line with local or regional guidance	26/02/2018
Daptomycin injection, infusion Cubicin® 1309/18	Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections. http://www.scottishmedicines.org.uk/files/advice/daptomicin_Cubicin_Non_Sub_FINAL_Jan_2018_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Darunavir, Cobicistat, Emtricitabine, Tenofovir tablets Symtuza® 1290/18	the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg). http://www.scottishmedicines.org.uk/files/advice/darunavir_Symtuza_Abbreviated_FINAL_Dec_2017_for_website.pdf	Routinely available in line with national guidance	26/02/2018
Desmopressin oral lyophilisate Noqdirna® 1218/17	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf	Routinely available in line with local or regional guidance	26/02/2018
Eluxadoline tablets Truberzi® 1292/18	in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D). http://www.scottishmedicines.org.uk/files/advice/eluxadoline_Truberzi_FINAL_Dec_2017_Amended_14.12.17_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir tablets Stribild® 1310/18	Treatment of HIV-1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild • and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate. http://www.scottishmedicines.org.uk/files/advice/elvit_cobic_emtric_Stribild_Non_Sub_FINAL_Jan_2018_with_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Fluticasone, Umeclidinium, Vilanterol inhalation powder Trelegy® Ellipta® 1303/18	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β_2 -agonist. http://www.scottishmedicines.org.uk/files/advice/fluticasone_furoate_Trelegy_Ellipta_Abbreviated_FINAL_Jan_2018_for_website.pdf	Routinely available in line with national guidance	26/02/2018
Levonorgestrel intrauterine delivery system Kyleena® 1299/18	Contraception for up to 5 years. http://www.scottishmedicines.org.uk/files/advice/levonorgestrel_Kyleena_FINAL_Jan_2018_for_website.pdf	Routinely available in line with national guidance	26/02/2018
Metformin MR tablets Glucophage SR® 1308/18	Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: - at high risk for developing overt type 2 diabetes mellitus and - still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months. http://www.scottishmedicines.org.uk/files/advice/metformin_hydrochloride_Glucophage_Non_Sub_FINAL_Dec_2017_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Nivolumab infusion Opdivo® 1285/18	Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Dec_2017_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Obinutuzumab infusion Gazyvaro® 1286/18	Obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma. http://www.scottishmedicines.org.uk/files/advice/obinutuzumab_Gazyvaro_FINAL_Dec_2018_Amended_14.12.17_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Pasireotide injection Signifor® 1311/18	Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed. http://www.scottishmedicines.org.uk/files/advice/pasireotide_Signifor_Non_Sub_FINAL_Jan_2018_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Peginterferon alfa-2a injection Pegasys® 1312/18	Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. http://www.scottishmedicines.org.uk/files/advice/peginterferon_alfa-2a_Pegasys_Non_Sub_FINAL_Jan_2018_for_website.pdf	Not routinely available as not recommended for use in NHSScotland	26/02/2018
Pembrolizumab infusion Keytruda® 1291/18	Monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy. http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_Jan_2018_for_website.pdf	Routinely available in line with local or regional guidance	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Tofacitinib tablets Xeljanz® 1298/18	In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. http://www.scottishmedicines.org.uk/files/advice/tofacitinib_Xeljanz_FINAL_Jan_2018_Amended_05.02.17_for_website.pdf	Routinely available in line with local or regional guidance	26/02/2018